184 related articles for article (PubMed ID: 28653191)
21. Pioneering apoptosis-targeted cancer drug poised for FDA approval.
Mullard A
Nat Rev Drug Discov; 2016 Mar; 15(3):147-9. PubMed ID: 26931080
[No Abstract] [Full Text] [Related]
22. Suzanne Cory: Life-and-Death Switches: the Rise of BH3 Mimetics.
Trends Cancer; 2016 Oct; 2(10):537-539. PubMed ID: 28741484
[No Abstract] [Full Text] [Related]
23. Venetoclax (Venclexta) for chronic lymphocytic leukemia.
Med Lett Drugs Ther; 2016 Aug; 58(1500):101-2. PubMed ID: 27466751
[No Abstract] [Full Text] [Related]
24. Venetoclax: A new wave in hematooncology.
Mihalyova J; Jelinek T; Growkova K; Hrdinka M; Simicek M; Hajek R
Exp Hematol; 2018 May; 61():10-25. PubMed ID: 29477371
[TBL] [Abstract][Full Text] [Related]
25. Expression of BCL2 alternative proteins and association with outcome in CLL patients treated with venetoclax.
Marques-Piubelli ML; Schlette EJ; Khoury JD; Furqan F; Vega F; Soto LMS; Wistuba II; Wierda WG; Konopleva M; Ferrajoli A; Strati P
Leuk Lymphoma; 2021 May; 62(5):1129-1135. PubMed ID: 33327833
[TBL] [Abstract][Full Text] [Related]
26. Genomics of Resistance to Targeted Therapies.
Thangavadivel S; Woyach JA
Hematol Oncol Clin North Am; 2021 Aug; 35(4):715-724. PubMed ID: 34174982
[TBL] [Abstract][Full Text] [Related]
27. Venetoclax in Patients with Previously Treated Chronic Lymphocytic Leukemia.
Roberts AW; Stilgenbauer S; Seymour JF; Huang DCS
Clin Cancer Res; 2017 Aug; 23(16):4527-4533. PubMed ID: 28100580
[TBL] [Abstract][Full Text] [Related]
28. SOHO State of the Art Updates and Next Questions | Mechanisms of Resistance to BCL2 Inhibitor Therapy in Chronic Lymphocytic Leukemia and Potential Future Therapeutic Directions.
Bennett R; Thompson E; Tam C
Clin Lymphoma Myeloma Leuk; 2022 Nov; 22(11):795-804. PubMed ID: 35970756
[TBL] [Abstract][Full Text] [Related]
29. Deregulation and epigenetic modification of BCL2-family genes cause resistance to venetoclax in hematologic malignancies.
Thomalla D; Beckmann L; Grimm C; Oliverio M; Meder L; Herling CD; Nieper P; Feldmann T; Merkel O; Lorsy E; da Palma Guerreiro A; von Jan J; Kisis I; Wasserburger E; Claasen J; Faitschuk-Meyer E; Altmüller J; Nürnberg P; Yang TP; Lienhard M; Herwig R; Kreuzer KA; Pallasch CP; Büttner R; Schäfer SC; Hartley J; Abken H; Peifer M; Kashkar H; Knittel G; Eichhorst B; Ullrich RT; Herling M; Reinhardt HC; Hallek M; Schweiger MR; Frenzel LP
Blood; 2022 Nov; 140(20):2113-2126. PubMed ID: 35704690
[TBL] [Abstract][Full Text] [Related]
30. ABT-199 for chronic lymphocytic leukemia.
Seymour J
Clin Adv Hematol Oncol; 2014 Oct; 12(10):698-700. PubMed ID: 25658896
[No Abstract] [Full Text] [Related]
31. BIRC3 Expression Predicts CLL Progression and Defines Treatment Sensitivity via Enhanced NF-κB Nuclear Translocation.
Asslaber D; Wacht N; Leisch M; Qi Y; Maeding N; Hufnagl C; Jansko B; Zaborsky N; Villunger A; Hartmann TN; Greil R; Egle A
Clin Cancer Res; 2019 Mar; 25(6):1901-1912. PubMed ID: 30487125
[TBL] [Abstract][Full Text] [Related]
32. Inhibition of bromodomain and extra-terminal proteins increases sensitivity to venetoclax in chronic lymphocytic leukaemia.
Carrà G; Nicoli P; Lingua MF; Maffeo B; Cartellà A; Circosta P; Brancaccio M; Parvis G; Gaidano V; Guerrasio A; Saglio G; Taulli R; Morotti A
J Cell Mol Med; 2020 Jan; 24(2):1650-1657. PubMed ID: 31821686
[TBL] [Abstract][Full Text] [Related]
33. Resistance to ABT-199 induced by microenvironmental signals in chronic lymphocytic leukemia can be counteracted by CD20 antibodies or kinase inhibitors.
Thijssen R; Slinger E; Weller K; Geest CR; Beaumont T; van Oers MH; Kater AP; Eldering E
Haematologica; 2015 Aug; 100(8):e302-6. PubMed ID: 25957396
[No Abstract] [Full Text] [Related]
34. Found in Translation: How Preclinical Research Is Guiding the Clinical Development of the BCL2-Selective Inhibitor Venetoclax.
Leverson JD; Sampath D; Souers AJ; Rosenberg SH; Fairbrother WJ; Amiot M; Konopleva M; Letai A
Cancer Discov; 2017 Dec; 7(12):1376-1393. PubMed ID: 29146569
[TBL] [Abstract][Full Text] [Related]
35. Pharmacokinetics of Venetoclax, a Novel BCL-2 Inhibitor, in Patients With Relapsed or Refractory Chronic Lymphocytic Leukemia or Non-Hodgkin Lymphoma.
Salem AH; Agarwal SK; Dunbar M; Enschede SL; Humerickhouse RA; Wong SL
J Clin Pharmacol; 2017 Apr; 57(4):484-492. PubMed ID: 27558232
[TBL] [Abstract][Full Text] [Related]
36. Identification of recurrent genomic alterations in the apoptotic machinery in chronic lymphocytic leukemia patients treated with venetoclax monotherapy.
Popovic R; Dunbar F; Lu C; Robinson K; Quarless D; Warder SE; Mukherjee N; Pesko J; Souers AJ; Waring JF; Davids MS; Tausch E; Stilgenbauer S; Ross JA; Leverson JD; Kim SY; Chyla BJ
Am J Hematol; 2022 Feb; 97(2):E47-E51. PubMed ID: 34779028
[No Abstract] [Full Text] [Related]
37. Venetoclax: A First-in-Class Oral BCL-2 Inhibitor for the Management of Lymphoid Malignancies.
King AC; Peterson TJ; Horvat TZ; Rodriguez M; Tang LA
Ann Pharmacother; 2017 May; 51(5):410-416. PubMed ID: 28056525
[TBL] [Abstract][Full Text] [Related]
38. Targeting anti-apoptotic BCL2 family proteins in haematological malignancies - from pathogenesis to treatment.
Vogler M; Walter HS; Dyer MJS
Br J Haematol; 2017 Aug; 178(3):364-379. PubMed ID: 28449207
[TBL] [Abstract][Full Text] [Related]
39. How I treat chronic lymphocytic leukemia after venetoclax.
Lew TE; Tam CS; Seymour JF
Blood; 2021 Aug; 138(5):361-369. PubMed ID: 33876212
[TBL] [Abstract][Full Text] [Related]
40. The BET bromodomain inhibitor CPI203 overcomes resistance to ABT-199 (venetoclax) by downregulation of BFL-1/A1 in in vitro and in vivo models of MYC+/BCL2+ double hit lymphoma.
Esteve-Arenys A; Valero JG; Chamorro-Jorganes A; Gonzalez D; Rodriguez V; Dlouhy I; Salaverria I; Campo E; Colomer D; Martinez A; Rymkiewicz G; Pérez-Galán P; Lopez-Guillermo A; Roué G
Oncogene; 2018 Apr; 37(14):1830-1844. PubMed ID: 29353886
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]